Mytesi is Effective For Diarrhea by HIV-positive People
Mytesi (Fulyxaq) anti-diarrheal 125 mg pill, taken twice a day, in the only approved drug by the FDA for treating noninfectious diarrhea by people living with HIV showed great efficiency in the number of clinical trials and the results of the research were presented at the International AIDS Society Conference on HIV Science, ended the last week in Paris.
In one of the trials more than 270 people living with HIV kept on taking drugs for diarrhea and the drug showed the 70% efficiency. The trial continued for 20 weeks.
“Mytesi achieves much greater reductions in HIV-related diarrhea than was apparent in the ADVENT primary responder analysis. Most patients saw meaningful reductions in diarrhea, with more than 75% experiencing at least a 50% reduction and more than half of patients experiencing complete resolution of diarrhea at week 24. I think it is important to note that results were consistent regardless of use of a protease inhibitor or the cause of the diarrhea” - said Rodger D. MacArthur, MD, from the Medical College of Georgia in Augusta.
“With an estimated 20% of the more than 36 million people currently living with HIV suffering from diarrhea, there are more than seven million patients worldwide who may benefit from the reduction in diarrhea that can be achieved with Mytesi therapy,” - said Lisa Conte, Jaguar’s president and CEO and Napo’s interim CEO.
